Inke Revenue and Competitors

Barcelona, Germany

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Inke's estimated annual revenue is currently $20.9M per year.(i)
  • Inke's estimated revenue per employee is $201,000

Employee Data

  • Inke has 104 Employees.(i)
  • Inke grew their employee count by 32% last year.

Inke's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$17.7M887%N/AN/A
#2
$89.4M4459%N/AN/A
#3
$32.4M16125%N/AN/A
#4
$44.4M2217%N/AN/A
#5
$120.2M42717%$446.2MN/A
#6
$54.3M27010%N/AN/A
#7
$49.6M24752%N/AN/A
#8
$21.9M109-1%N/AN/A
#9
$16.5M824%N/AN/A
#10
$26.7M13325%N/AN/A
Add Company

What Is Inke?

Inke S.A., is focused in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes, mainly for use in Respiratory.\n\nBased in Barcelona (Spain) and counting more than twenty years’ experience in micronization, Inke is in continuous international expansion since 1998, delivering APIs all over the world, including US, Europe and Japan.\n\nInke develops, patents and implements its own synthesis routes for the manufacture of active substances. Given the specific requirements for these products, this strategic commitment has involved an increase in the level of technical and regulatory collaboration with our customers.\n\nInke has been successfully inspected by every major global authority for a wide array of products (last US-FDA inspection was in April 2019). For the last two decades, the company has made strong strides to become a prestige provider of respiratory APIs for inhalation. \n\nTo learn more about our expertise in inhalation therapies, please get in touch at email contact-inke@inke.es

keywords:N/A

N/A

Total Funding

104

Number of Employees

$20.9M

Revenue (est)

32%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$26.4M10465%N/A
#2
$14.6M10446%N/A
#3
N/A10432%N/A
#4
$34.1M10584%N/A
#5
N/A1077%N/A